The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Open accessAbstract
BACKGROUND: Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with previously treated metastatic melanoma. We conducted a phase 3 study of ipilimumab (10 mg per kilogram) plus dacarbazine in patients with previously untreated metastatic melanoma. METHODS: We randomly assigned 502 patients with previously untreated metastatic melanoma, in a 1:1 ratio, to ipilimumab (10 mg per kilogram) plus dacarbazine (850 mg per square meter of body-surface area) or dacarbazine (850 mg per square meter) plus placebo, given at weeks 1, 4, 7, and 10, followed by dacarbazine alone every 3 weeks through week 22. Patients with stable disease or an objective response and no dose-limiting toxic effects received ipilimumab or placebo every 12 weeks thereafter as maintenance therapy. The primary end point was overall survival. RESULTS: Overall survival was significantly longer in the group receiving ipilimumab plus dacarbazine than in the group receiving dacarbazine plus placebo (11.2 months vs. 9.1 months, with higher survival rates in the ipilimumab-dacarbazine group at 1 year (47.3% vs. 36.3%), 2 years (28.5% vs. 17.9%), and 3 years (20.8% vs. 12.2%) (hazard ratio for death, 0.72; P<0.001). Grade 3 or 4 adverse events occurred in 56.3% of patients treated with ipilimumab plus dacarbazine, as compared with 27.5% treated with dacarbazine and placebo (P<0.001). No drug-related deaths or gastrointestinal perforations occurred in the ipilimumab-dacarbazine group. CONCLUSIONS: Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dacarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma. The types of adverse events were consistent with those seen in prior studies of ipilimumab; however, the rates of elevated liver-function values were higher and the rates of gastrointestinal events were lower than expected on the basis of prior studies. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00324155.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, approximately 20% of patients who received ipilimumab achieved long-term survival greater than three years, with survival of 10 years noted for some patients (38,42).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [38]
In the citing paper
“Ipilimumab (anti-CTLA4) was the first ICT to gain FDA approval in 2011 for the treatment of metastatic melanoma, on the basis of phase III trials demonstrating improvements in overall survival compared with vaccine or chemotherapy (37,38).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [38]
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,653
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationAtkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Margolin, K. A., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,043
Eguchi, S., Takatsuki, M., Soyama, A., Hara, T., Hidaka, M., Muraoka, I., & Kanematsu, T. (2011) · Hepatogastroenterology · doi:10.5754/hge11589 · Cited by 1,756
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Middleton, M. R., Grob, J., Aaronson, N. K., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M. E., Aamdal, S., Cebon, J. S., Coates, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.158 · Cited by 1,270
Self-citationWolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Self-citationImmunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervás‐Stubbs, S., Glennie, M. J., Pardoll, D. M., & Chen, L. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2051 · Cited by 634
Flagged first, then by citations
1 of the 29 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Mokyr MB, 1998, Cancer Res, 58, 5301
Cited by
Sorted by citations
Items 901–1,000 of 1,022
Tremelimumab: research and clinical development
Ibarrondo, F. J., Comin-Anduix, B., & Escuin-Ordinas, H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s65802 · Cited by 86
Heppt, M. V., Eigentler, T., Kähler, K. C., Herbst, R. A., Göppner, D., Gambichler, T., Ulrich, J., Dippel, E., Loquai, C., Schell, B., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1856-z · Cited by 84
Yi, J. S., Ready, N., Healy, P. N., Dumbauld, C., Osborne, R. J., Berry, M. F., Shoemaker, D., Clarke, J. M., Crawford, J., Tong, B. C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2005 · Cited by 84
Current status and perspectives in immunotherapy for metastatic melanoma
Marconcini, R., (IMI), F. T. I. M. I., Spagnolo, F., Stucci, L. S., Ribero, S., Marra, E., Rosa, F. D., Picasso, V., Guardo, L. D., Cimminiello, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23746 · Cited by 84
Diao, K., Bian, S. X., Routman, D. M., Cheng, Y., Ye, J. C., Wagle, N. A., Wong, M. K. K., Zada, G., & Chang, E. L. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2880-y · Cited by 84
Wang, S., Zhang, J., He, Z., Wu, K., & Liu, X. (2019) · International Journal of Cancer · doi:10.1002/ijc.32327 · Cited by 85
Regev, A., Avigan, M., Kiazand, A., Vierling, J. M., Lewis, J. H., Omokaro, S. O., Bisceglie, A. M. D., Fontana, R. J., Bonkovsky, H. L., Freston, J. W., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102514 · Cited by 86
Gut Microbiota: Its Potential Roles in Pancreatic Cancer
Li, Q., Jin, M., Liu, Y., & Jin, L. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.572492 · Cited by 89
Alterations of DNA damage repair in cancer: from mechanisms to applications
Jiang, M., Jia, K., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., He, Y., & Zhou, C. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2920 · Cited by 87
The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
Russell, B. L., Sooklal, S. A., Malindisa, S. T., Daka, L. J., & Ntwasa, M. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.641428 · Cited by 86
Palmer, A. C., Izar, B., Hwangbo, H., & Sorger, P. K. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2275 · Cited by 85
Ni, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 85
Tandon, P., Bourassa‐Blanchette, S., Bishay, K., Parlow, S., Laurie, S. A., & McCurdy, J. D. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000213 · Cited by 85
Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy
Mozzillo, N., Simeone, E., Benedetto, L., Curvietto, M., Giannarelli, D., Gentilcore, G., Camerlingo, R., Capone, M., Madonna, G., Festino, L., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008842 · Cited by 83
How Does Ionizing Irradiation Contribute to the Induction of Anti-Tumor Immunity?
Rubner, Y., Wunderlich, R., Rühle, P.-F., Kulzer, L., Werthmöller, N., Frey, B., Weiss, E., Keilholz, L., Fietkau, R., & Gaipl, U. S. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00075 · Cited by 84
Immune checkpoint modulation: Rational design of combination strategies
Zamarin, D., & Postow, M. A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.003 · Cited by 85
Zheng, Y., Dou, Y., Duan, L., Cong, C., Gao, A., Lai, Q., & Sun, Y. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.02.003 · Cited by 83
Schadendorf, D., Amonkar, M. M., Stroyakovskiy, D., Levchenko, E., Gogas, H. J., de Braud, F., Grob, J., Bondarenko, I., Garbe, C., Lebbé, C., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.03.004 · Cited by 83
Self-citationActive immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives
Milani, A., Sangiolo, D., Montemurro, F., Aglietta, M., & Valabrega, G. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt133 · Cited by 83
Luke, J. J., & Hodi, F. S. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0391 · Cited by 84
Klemen, N. D., Wang, M., Feingold, P. L., Cooper, K., Pavri, S. N., Han, D., Detterbeck, F. C., Boffa, D. J., Khan, S. A., Olino, K. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0672-3 · Cited by 83
Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer’s Achilles’ Heel
Caracciolo, D., Riillo, C., Martino, M. T. D., Tagliaferri, P., & Tassone, P. (2021) · Cancers · doi:10.3390/cancers13061392 · Cited by 87
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
Eroglu, Z., Kim, D. W., Wang, X., Camacho, L. H., Chmielowski, B., Seja, E., Villanueva, A., Ruchalski, K. L., Glaspy, J. A., Kim, K. B., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.012 · Cited by 87
Aruga, A., Takeshita, N., Kotera, Y., Okuyama, R., Matsushita, N., Ohta, T., Takeda, K., & Yamamoto, M. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-61 · Cited by 83
Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens
Hebeisen, M., Allard, M., Gannon, P. O., Schmidt, J., Speiser, D. E., & Rufer, N. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00582 · Cited by 85
Gastric cancer and the epoch of immunotherapy approaches
Niccolai, E., Taddei, A., Prisco, D., & Amedei, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i19.5778 · Cited by 84
Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC
Brockwell, N. K., Owen, K. L., Zanker, D. J., Spurling, A., Rautela, J., Duivenvoorden, H. M., Baschuk, N., Caramia, F., Loi, S., Darcy, P. K., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0150 · Cited by 83
Quirk, S. K., Shure, A. K., & Agrawal, D. K. (2015) · Translational research · doi:10.1016/j.trsl.2015.06.005 · Cited by 82
Metastatic melanoma treatment: Combining old and new therapies
Davey, R. J., van der Westhuizen, A., & Bowden, N. A. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.011 · Cited by 90
Khoja, L., Atenafu, E. G., Templeton, A. J., Qye, Y., Chappell, M. A., Saibil, S. D., Hogg, D., Butler, M. O., & Joshua, A. M. (2016) · Cancer Medicine · doi:10.1002/cam4.878 · Cited by 82
Jain, A., Lipson, E. J., Sharfman, W. H., Brant, S. R., & Lazarev, M. G. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i11.2023 · Cited by 82
Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies
Fishman, J. A., Hogan, J. I., & Maus, M. V. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1025 · Cited by 83
Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer
Principe, D. R., Chiec, L. S., Mohindra, N. A., & Munshi, H. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684098 · Cited by 85
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
Principe, D. R., Kamath, S. D., Korc, M., & Munshi, H. G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108111 · Cited by 83
Newly developed 3D in vitro models to study tumor–immune interaction
Mu, P., Zhou, S., Lv, T., Xia, F., Shen, L., Wan, J., Wang, Y., Zhang, H., Cai, S., Peng, J., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02653-w · Cited by 87
Shin, J. H., Park, H. B., Oh, Y. M., Lim, D. P., Lee, J. E., Seo, H. H., Lee, S. J., Eom, H., Kim, I.-H., Lee, S. H., et al. (2012) · Blood · doi:10.1182/blood-2011-09-380519 · Cited by 84
Aranda, F., Vacchelli, E., Obrist, F., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Cremer, I., ter Meulen, J. H., Zitvogel, L., Kroemer, G., et al. (2014) · OncoImmunology · doi:10.4161/onci.29179 · Cited by 85
Re‐adapting T cells for cancer therapy: from mouse models to clinical trials
Stromnes, I. M., Schmitt, T. M., Chapuis, A. G., Hingorani, S. R., & Greenberg, P. D. (2013) · Immunological Reviews · doi:10.1111/imr.12141 · Cited by 82
Pharmacogenomic biomarkers for personalized cancer treatment
Rodríguez‐Antona, C., & Tarón, M. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12321 · Cited by 82
Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer
Muir, C. A., Menzies, A. M., Clifton-Bligh, R. J., & Tsang, V. (2020) · Thyroid · doi:10.1089/thy.2020.0032 · Cited by 82
The Mechanism of Stimulating and Mobilizing the Immune System Enhancing the Anti-Tumor Immunity
Wu, Z., Li, S., & Zhu, X. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.682435 · Cited by 82
Ipilimumab‐induced toxicities and the gastroenterologist
Cheng, R., Cooper, A. J., Kench, J. G., Watson, G., Bye, W. A., McNeil, C. M., & Shackel, N. A. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12888 · Cited by 81
Iwanuma, Y., Tomita, N., Amano, T., Isayama, F., Tsurumaru, M., Hayashi, T., & Kajiyama, Y. (2011) · Journal of Gastroenterology · doi:10.1007/s00535-011-0490-y · Cited by 81
New Challenges in Endpoints for Drug Development in Advanced Melanoma
Ribas, A., Hersey, P., Middleton, M. R., Gogas, H. J., Flaherty, K. T., Sondak, V. K., & Kirkwood, J. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2323 · Cited by 81
Cancer Immunology and Immunotherapy
Sukari, A. W., Nagasaka, M., Al‐Hadidi, A., & Lum, L. G. (2016) · Anticancer Research · doi:10.21873/anticanres.11144 · Cited by 81
Bunchorntavakul, C., & Reddy, K. R. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2016.08.009 · Cited by 81
Tietze, J., Angelova, D., Heppt, M., Reinholz, M., Murphy, W., Spannagl, M., Ruzicka, T., & Berking, C. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.031 · Cited by 79
Diao, K., Bian, S. X., Routman, D. M., Cheng, Y., Kim, P. E., Wagle, N. A., Wong, M. K. K., Zada, G., & Chang, E. L. (2018) · Journal of neurosurgery · doi:10.3171/2017.7.jns171286 · Cited by 81
Immune checkpoint inhibitors: therapeutic advances in melanoma.
Márquez‐Rodas, I., Cerezuela-Fuentes, P., Soria, A., Berrocal, A., Riso, A. A., González‐Cao, M., & Martín‐Algarra, S. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.10.27 · Cited by 82
Glioblastoma multiforme targeted therapy: The Chlorotoxin story
Cohen‐Inbar, O., & Zaaroor, M. (2016) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2016.04.012 · Cited by 80
Gibson, R., Delaune, J. D., Szady, A. D., & Markham, M. J. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-216228 · Cited by 80
Haque, W. M., Verma, V., Butler, E. B., & Teh, B. S. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000264 · Cited by 83
Nederlof, I., Isaeva, O. I., de Graaf, M., Gielen, R., Bakker, N. A. M., Rolfes, A. L., Garner, H., Boeckx, B., Traets, J. J. H., Mandjes, I. A. M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03249-3 · Cited by 88
Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors
Chen, T. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv156 · Cited by 82
Self-citationThe evolutionary legacy of immune checkpoint inhibitors
Kaushik, I., Ramachandran, S., Zabel, C., Gaikwad, S., & Srivastava, S. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.020 · Cited by 79
Spanggaard, I., Snoj, M., Cavalcanti, A., Bouquet, C., Serša, G., Robert, C., Čemažar, M., Dam, E., Vasseur, B., Attali, P., et al. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2012.240 · Cited by 79
Self-citationImmunotherapy of melanoma: Present options and future promises
Rotte, A., Bhandaru, M., Zhou, Y., & McElwee, K. J. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9542-0 · Cited by 80
Corrie, P. G., Hategan, M., Fife, K. M., & Parkinson, C. (2014) · British Medical Bulletin · doi:10.1093/bmb/ldu019 · Cited by 83
Au, K. P., & Chok, K. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i45.5081 · Cited by 79
Manukian, G., Bar‐Ad, V., Lü, B., Argiris, A. E., & Johnson, J. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00122 · Cited by 83
Rivero, J. D., Cordes, L. M., Kłubo-Gwieździńska, J., Madan, R. A., Nieman, L. K., & Gulley, J. L. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0470 · Cited by 79
Desnoyer, A., Broutin, S., Delahousse, J., Maritaz, C., Blondel, L., Mir, O., Chaput, N., & Paci, A. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.01.003 · Cited by 79
Torino, F., Barnabei, A., Vecchis, L. D., Salvatori, R., & Corsello, S. M. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0404 · Cited by 79
Diaz, C. M., Chiappori, A., Aurisicchio, L., Bagchi, A., Clark, J., Dubey, S. A., Fridman, A., Fabregas, J. C., Marshall, J. L., Scarselli, E., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-62 · Cited by 80
Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
Li, X., Song, W., Shao, C., Shi, Y., & Han, W. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0086-z · Cited by 79
In-situ tumor vaccination: Bringing the fight to the tumor
Pierce, R. H., Campbell, J. S., Pai, S. I., Brody, J., & Kohrt, H. E. K. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1049779 · Cited by 80
Connolly, K., Manders, P., Earls, P., & Epstein, R. J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.08.005 · Cited by 79
Kelderman, S., van der Kooij, M. K., van den Eertwegh, A. J. M., Soetekouw, P. M. M. B., Jansen, R. L. H., van den Brom, R. R. H., Hospers, G. A. P., Haanen, J. B. A. G., Kapiteijn, E., & Blank, C. U. (2013) · Acta Oncologica · doi:10.3109/0284186x.2013.786839 · Cited by 78
Neoepitopes as Cancer Immunotherapy Targets: Key Challenges and Opportunities
Brennick, C. A., George, M. M., Corwin, W. L., Srivastava, P. K., & Ebrahimi-Nik, H. (2017) · Immunotherapy · doi:10.2217/imt-2016-0146 · Cited by 80
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
Shen, H., Yang, E. S.-H., Conry, M., Fiveash, J. B., Contreras, C. M., Bonner, J. A., & Shi, L. Z. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.06.006 · Cited by 78
Brouwer, N. J., Verdijk, R. M., Heegaard, S., Marinkovic, M., Esmaeli, B., & Jager, M. J. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100971 · Cited by 81
Zhou, B., Gao, Y., Zhang, P., & Chu, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693609 · Cited by 81
AMPK–a key factor in crosstalk between tumor cell energy metabolism and immune microenvironment?
Wang, N., Wang, B., Maswikiti, E. P., Yu, Y., Song, K., Ma, C., Han, X., Ma, H., Deng, X., Yu, R., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02011-5 · Cited by 83
Kunz, M. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-5590-1_6 · Cited by 86
Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons
Hollebecque, A., Malka, D., Ferté, C., Ducreux, M. P., & Boige, V. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.12.005 · Cited by 79
Martin, K., Müller, P., Schreiner, J., Prince, S. S., Lardinois, D., Heinzelmann-Schwarz, V. A., Thommen, D. S., & Zippelius, A. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1565-4 · Cited by 78
Regulation of Innate and Adaptive Antitumor Immunity by IAP Antagonists
Dougan, S. K., & Dougan, M. L. (2018) · Immunotherapy · doi:10.2217/imt-2017-0185 · Cited by 80
Abdel-Rahman, O. M., Elhalawani, H. M., & Fouad, M. (2015) · Future Oncology · doi:10.2217/fon.15.118 · Cited by 77
Galluzzi, L., Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.19549 · Cited by 81
Becker, J. C., Andersen, M. H., Hofmeister, V., Wobser, M., Frey, L. M., Sandig, C., Walter, S., Singh‐Jasuja, H., Kämpgen, E., Opitz, A., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1266-9 · Cited by 77
Radiotherapy and immune checkpoints inhibitors for advanced melanoma
Filippi, A. R., Fava, P., Badellino, S., Astrua, C., Ricardi, U., & Quaglino, P. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.06.003 · Cited by 79
Review of immune checkpoint inhibitors in immuno-oncology
Jacob, J. B., Jacob, M. K., & Parajuli, P. (2021) · Advances in pharmacology · doi:10.1016/bs.apha.2021.01.002 · Cited by 80
Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma.
Mansh, M. D. (2011) · Europe PMC (PubMed Central) · Cited by 77
Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
Albertini, M. R., Hank, J. A., Gadbaw, B., Kostlevy, J., Haldeman, J., Schalch, H., Gan, J., Kim, K., Eickhoff, J. C., Gillies, S. D., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1286-5 · Cited by 77
Kunert, A., Straetemans, T., Govers, C., Lamers, C., Mathijssen, R. H. J., Sleijfer, S., & Debets, R. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00363 · Cited by 77
The Wnts of change: How Wnts regulate phenotype switching in melanoma
Webster, M. R., Kugel, C. H., & Weeraratna, A. T. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.10.002 · Cited by 81
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma
Jacquelot, N., Enot, D. P., Flament, C., Vimond, N., Blattner, C., Pitt, J. M., Yamazaki, T., Roberti, M. P., Daillère, R., Vétizou, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci80071 · Cited by 79
Self-citationHolmgaard, R., Brachfeld, A., Gasmi, B., Jones, D. R., Mattar, M. S., Doman, T. N., Murphy, M. Y., Schaer, D., Wolchok, J. D., & Merghoub, T. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1151595 · Cited by 80
Self-citationUveal melanoma as a target for immune-therapy
Oliva, M., Rullan, A., & Piulats, J. M. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.05.04 · Cited by 77
Sullivan, R. J., Atkins, M. B., Kirkwood, J. M., Agarwala, S. S., Clark, J. I., Ernstoff, M. S., Fecher, L. A., Gajewski, T. F., Gastman, B., Lawson, D. H., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0362-6 · Cited by 80
Self-citationBalatoni, T., Mohos, A., Papp, E., Sebestyén, T., Liszkay, G., Oláh, J., Varga, A., Lengyel, Z., Emri, G., Gaudi, I., et al. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2072-1 · Cited by 76
MiR-377 targets E2F3 and alters the NF-kB signaling pathway through MAP3K7 in malignant melanoma
Zehavi, L., Schayek, H., Jacob‐Hirsch, J., Sidi, Y., Leibowitz‐Amit, R., & Avni, D. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0338-9 · Cited by 77
Emerging Immunotherapies in the Treatment of Non–small Cell Lung Cancer (NSCLC)
Langer, C. J. (2014) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000059 · Cited by 77
Wilgenhof, S., Corthals, J., Nuffel, A. M. T. V., Benteyn, D., Heirman, C., Bonehill, A., Thielemans, K., & Neyns, B. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1642-8 · Cited by 76
Wolchok, J. D. (2012) · Annals of Oncology · doi:10.1093/annonc/mds258 · Cited by 76
Self-citationS3‐Guideline “Diagnosis, therapy and follow‐up of melanoma” – short version
Pflugfelder, A., Kochs, C., Blum, A., Capellaro, M., Czeschik, J. C., Dettenborn, T., Dill, D., Dippel, E., Eigentler, T., Feyer, P. C., et al. (2013) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.12044 · Cited by 76
Self-citationThe use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma
Lee, B., Wong, A. N. M., Kee, D., Neeson, P. J., Shackleton, M. J., McArthur, G. A., & Sandhu, S. K. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw056 · Cited by 76
Vogt-Koyanagi-Harada–like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma
Bricout, M., Petre, A., Amini‐Adlé, M., Bezza, W., Sève, P., Kodjikian, L., Dalle, S., & Thomas, L. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000154 · Cited by 76
Self-citationBroman, K. K., Dossett, L. A., Sun, J. X., Eroglu, Z., & Zager, J. S. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1607289 · Cited by 76
The role of regulatory T cells in the pathogenesis and treatment of prostate cancer
Karpisheh, V., Mousavi, S. M., Sheykholeslami, P. N., Fathi, M., Saray, M. M., Maleki, L. A., Jafari, R., Zolbanin, N. M., & Jadidi‐Niaragh, F. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119132 · Cited by 78
Metadata
- Authors
- Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., Davidson, N., Richards, J., Maio, M., Hauschild, A., Miller, W. H., Gascon, P., Lotem, M., Harmankaya, K., Ibrahim, R., Francis, S., Chen, T.-T., Humphrey, R., Hoos, A., & Wolchok, J. D.
- Affiliations
- Institut Gustave Roussy (FR)
- Hôpital Lyon Sud (FR)
- Dnipro State Medical University (UA)
- Angeles Clinic and Research Institute (US)
- Moffitt Cancer Center (US)
- Cliniques Universitaires Saint-Luc (BE)
- European Institute of Oncology (IT)
- Hôpital de la Timone (FR)
- Mid Essex Hospital Services NHS Trust (GB)
- Oncology Specialists (US)
- University of Siena (IT)
- Christian-Albrechts-Universität zu Kiel (DE)
- Hadassah Medical Center (IL)
- Medical University of Vienna (AT)
- Bristol-Myers Squibb (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-06-30
- Volume
- 364
- Issue
- 26
- Pages
- 2517-2526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2123363005
- Cited by
- 4,496
- References
- 29
- Citations by year
- 2026: 58 · 2025: 99 · 2024: 148 · 2023: 173 · 2022: 213 · 2021: 249 · 2020: 289 · 2019: 283 · 2018: 374 · 2017: 415 · 2016: 466 · 2015: 476 · 2014: 400 · 2013: 392 · 2012: 346
- FWCI
- 195.50
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- ipilimumab, dacarbazine, metastatic melanoma, combination immunotherapy, CTLA-4 blockade, overall survival, adverse events, liver dysfunction, maintenance therapy, immune-related adverse events, immune checkpoint inhibitors, progression-free survival
- MeSH terms
- Ipilimumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dacarbazine, Double-Blind Method, Female, Humans, Liver Function Tests, Male, Melanoma, Middle Aged, Proportional Hazards Models, Disease Progression, Antineoplastic Agents, Alkylating, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
